Atlas Trials

Ulixertinib (BVD-523) and Hydroxychloroquine in Patients W Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas

Clinical trial NCT04145297 · COMPLETED

Trial details

NCT number
NCT04145297
Sponsor
University of Utah
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Gastrointestinal Neoplasms
Start date
2020-03-17
Primary completion
2022-06-10
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.